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Purpose: Elderly cancer patients often have co-morbidities and other characteristics that 
make the selection of optimal treatment more complex. The introduction of targeted therapies 
in colorectal cancer has further complicated this problem. This review will focus on the role of 
the EGFR antibody cetuximab in elderly patients.
Methods: We have reviewed the available evidence in the literature to evaluate the results of 
therapy with cetuximab, alone or in combination with chemotherapy, with a focus on elderly 
patients with metastatic colorectal cancer (mCRC).
Results: In patients with mCRC, combination chemotherapy prolongs median survival to 
more than 18 months and even around 24 months in combination with cetuximab in selected 
patients. No prospective studies have evaluated cetuximab in elderly patients. However, sub-
group analyses from randomized trials and retrospective analysis suggest that the efﬁ  cacy of 
chemotherapy and cetuximab is maintained in ﬁ  t elderly patients, but with slightly increased 
but acceptable toxicity.
Conclusion: No prospective cetuximab studies have been conducted solely in a population of 
elderly patients. However, available data suggest that outcomes in the ﬁ  t elderly mirror results 
observed in younger patients.
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Introduction
WHO deﬁ  nes an elderly person in the developed countries as a person with a 
chronological age of 65 years and above (65+ years). However aging is a heterogeneous 
process and the ‘chronological age’ is not always predicting of the ‘physiological 
age’. In many but not all clinical studies, 65+ years is used as cut-point for evaluating 
efﬁ  cacy and toxicity in younger and older patients.
The median age of patients with colorectal cancer (CRC) is 72 years at the time of 
the primary diagnosis. Approximately 70% of CRC patients are aged 65+ years and 40% 
are aged 75+ years thus making CRC cancer a disease primarily of the elderly. Despite 
this fact the elderly are under-represented in clinical trials.1–3 In addition, co-morbidity 
is often an exclusion criterion in clinical trials and thus elderly patients in clinical trials 
constitute a highly selected group. Therefore it is often difﬁ  cult to extrapolate results 
from clinical trials to the daily practice of treating the elderly patient.
In less than a decade the research and development of medical treatment modalities 
in patients with metastatic colorectal cancer (mCRC) have changed the treatment 
options from monotherapy with 5-ﬂ  uorouracil (FU) modulated by folinic acid (FA) 
to combination chemotherapy with irinotecan or oxaliplatin and very recently to 
chemotherapy in combination with targeted therapy.4
In 2004 two targeted therapies were approved in the USA and the EU for patients 
with mCRC, and are now used in daily practice: Cetuximab (Erbitux®), a monoclonal OncoTargets and Therapy 2009:2 18
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antibody blocking the epidermal growth factor receptor 
(EGFR) and bevacizumab (Avastin®) a monoclonal antibody 
targeting angiogenesis. Since then, panitumumab (Vectibix®), 
a human antibody against EGFR, has been approved as mono-
therapy in patients with KRAS wild-type mCRC.5,6
In this review we will summarize the present status of 
cetuximab in patients with mCRC with special attention 
to elderly patients. As cetuximab, is most frequently used 
in combination with chemotherapy, we will brieﬂ  y sum-
marize the current principles of chemotherapy in patients 
with mCRC.
Methods
To identify data on therapy with cetuximab in elderly 
patients with mCRC, we searched the databases Medline 
and ClinicalTrials.gov for relevant publications using the 
search terms colon cancer, CRC, elderly antibody therapy, 
monoclonal antibody, targeted therapy, cetuximab. Data on 
treatment and side effects were also identiﬁ  ed in relevant pub-
lications and from listings in recent overviews. Full reporting 
of ﬁ  nal results from important clinical trials often lags behind 
more preliminary reports in the abstract form. Therefore, 
we included data from abstracts to be able to present the 
most recent information on treatment. Abstracts presented 
at the annual meetings of ASCO, ASCO GI, AACR, ECCO/
ESMO from 2005 to 2008 were reviewed and included as 
applicable.
Palliative chemotherapy in patients 
with metastatic CRC
The modern era of combination chemotherapy started when it 
was shown that irinotecan prolonged median overall survival 
(OS) in patients resistant to FU/FA.7,8 Since then, the use of 
combination chemotherapy, both as ﬁ  rst and second line, has 
increased the life expectancy to nearly 2 years.9,10
First-line doublets (Table 1) increase response rates from 
20% to more than 40% and prolong progression-free survival 
(PFS) from 4 to 6 months to 6 to 8 months.9 Direct compari-
sons between different combinations (Table 1) with irinote-
can (eg, FOLFIRI or FLIRI) and oxaliplatin (eg, FOLFOX, 
XELOX or FLOX) demonstrate that nearly all doublets are 
equally effective with respect to response rate, median PFS 
and median OS.11–13 The most important exception to this 
statement is IFL which is too toxic and less active and should 
no longer be offered as a standard regimen.14
OS is correlated with the percentage of patients who 
receive all three agents (FU/FA, irinotecan and oxaliplatin) and 
the use of ﬁ  rst- and second-line combination chemotherapy 
Table 1 Selected randomized studies evaluating chemotherapy in patients with metastatic colorectal cancer
Author, year Regimen No of patients RR (%) Median PFS (months) Median OS (months)
FU/FA versus combination with irinotecan
  Saltz et al 200096 FU/FA
IFL
226
231
21
39*
4.3
7.0*
12.6
14.8*
  Douillard et al 200097 FU/FA
FOLFIRI
187
198
22
35*
4.4
6.7*
14.1
17.4*
  Köhne et al 200598 FU/FA
FUFIRI
216
214
32
54*
6.4
8.5*
16.9
20.1
5-FU/FA versus combination with oxaliplatin
  de Gramont et al 200099 FU/FA
FOLFOX
210
210
22
51*
6.2
9.0*
14.7
16.2
  Giacchetti et al 2000100 FU/FA
FOLFOX
100
100
12
34*
6.1
8.7*
19.9
19.4
Combination versus combination
  Tournigand et al 200411 FOLFOX
FOLFIRI
111
111
54
56
10.9
14.2
20.6
21.5
  Goldberg et al 200414 IFL
FOLFOX
264
267
31
45*
6.9
8.7*
15.0
19.5*
  Glimelius et al 200812 FLIRI
FOLFIRI
281
286
35
49*
9.4
9.0
19.4
19.0
  Cassidy et al 200813 XELOX
FOLFOX
1017
1017
47
48
8.0
8.5
19.8
19.6
*Signiﬁ  cant difference.
Abbreviations: FU/FA, 5-ﬂ  uorouracil/folinic acid; RR, response rate; PFS, progression-free survival; OS, overall survival.OncoTargets and Therapy 2009:2 19
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will assure that more patients are exposed to the three keys 
drugs.10,15–17 It is considered of minor importance which 
therapy is used as ﬁ  rst-line treatment and the general opinion 
at present is that the choice of ﬁ  rst-line therapy is mostly a 
matter of the adverse effects proﬁ  le.10,15–17
The most important and the most dangerous side effect 
from irinotecan is diarrhea, and careful information is very 
important.
The dose-limiting side effect of continuous therapy with 
oxaliplatin is chronic sensory neuropathy limiting the use 
of oxaliplatin beyond a cumulative dose of 1000 mg/m2, 
corresponding to 6 months of therapy.
Many patients are still in an excellent performance 
status despite progressive disease after treatments with 
different combinations of FU/FA, irinotecan and oxaliplatin. 
Third-line chemotherapy in these patients has poor efﬁ  cacy 
with response rate less than 5%, PFS less than 2 months and 
OS around 4 months and is not recommended outside clinical 
trials.18 The availability of targeted therapy has opened up 
new possibilities for these patients.
Duration of combination 
chemotherapy
At the time when FU/FA was the only choice, treatment was 
maintained until progression. This strategy was carried on 
with the introduction of doublets. However this strategy has 
to be revised as recent studies have shown that an intermit-
tent strategy compared with continuous use of chemotherapy 
does not compromise efﬁ  cacy.19,20
The overall conclusion of OPTIMOX1 and OPTIMOX2 
was that a total pause in treatment can not be recommended 
after only 3 months of treatment due to an inferior OS.19,21 
However single-drug treatment or biological treatment may 
be used as maintenance therapy.19,21 A new analysis of these 
data showed that a treatment pause is fully acceptable if 
therapy is given for at least 6 months.22
Elderly patients tolerate and beneﬁ  t 
from combination chemotherapy
Several studies have shown that elderly patients enrolled in 
trials have similar beneﬁ  ts and comparable toxicity proﬁ  les 
of single agent ﬂ  uoropyrimidines compared to younger 
patients.23–26
The only exception is neutropenia, which was found  more 
often in elderly patients in a pooled analysis of 7 adjuvant 
trials with single agent FU.27
In a pooled analysis of safety and efﬁ  cacy of FOLFOX4 
in 3742 patients included in 4 clinical trials (adjuvant and 
palliative therapy) it was shown that FOLFOX4 maintains 
its efﬁ  cacy and safety ratio in elderly patients (70+ years). 
However, grade 3–4 neutropenia and thrombocytopenia were 
observed more frequently in elderly patients.28
In a recent combined analysis of more than 2500 patients 
treated with different irinotecan/FU schedules in 4 ﬁ  rst-line 
phase III trials, the authors concluded that elderly patients 
(70+ years) who fulﬁ  lled the inclusion criteria of these trials 
had similar beneﬁ  ts of treatment and similar risk of toxicity 
as younger patients and these results were also conﬁ  rmed in 
systematic reviews.29–31
Nevertheless, a recent large community-based study 
demonstrated that elderly patients (age 65+ years) were 
less likely to receive ﬁ  rst-line doublet chemotherapy and 
also less likely to receive irinotecan, oxaliplatin, and 
bevacizumab during the entire course of the disease. In 
this unselected group of patients the elderly had a shorter 
median survival (19.1 months versus 24.5 months) and more 
toxicity-related hospitalizations (21% versus 11%) than the 
younger patients.32 This discrepancy between the results 
from subgroup analyses in randomized clinical trials and this 
community-based study is probably due to a higher propor-
tion of patients with co-morbidities and poorer performance 
status in the unselected community-based study than reported 
in randomized clinical trials. Therefore it is important to 
distinguish between the frail elderly patients with co-morbid-
ity and poor performance status and the ﬁ  t elderly patient, as 
ﬁ  t elderly tolerate combination chemotherapy and have the 
same beneﬁ  t as younger patients.30,31
Cetuximab for treatment
of metastatic CRC
Pharmacodynamics
Cetuximab is an human-murine chimeric antibody directed 
against the ligand-binding site of EGFR. The EGFR is a trans-
membrane glycoprotein that is involved in signaling pathways 
affecting cellular growth, differentiation, and proliferation.33 It 
is a member of the HER tyrosine kinase growth factor recep-
tor family and is expressed in many types of normal tissues. 
Binding of ligands to the extracellular domain promotes 
dimerization of the HER receptor family, and activates 
intracellular downstream kinases. Downstream effectors are 
among others the RAF/MEK/ERK pathway as well as the 
PI3K/PTEN/AKT pathway. Central to both of these pathways 
are RAS regulatory proteins, among these KRAS.
Up-regulation of the EGFR is found in a large number of 
cancers. Sixty to eighty percent of CRC has up-regulation OncoTargets and Therapy 2009:2 20
Pfeiffer et al
of the EGFR.34 However the clinical beneﬁ  t of cetuximab 
appears to be independent of expression of EGFR.35–37
Normal/non-mutated KRAS (wild-type) is vital for effect 
of cetuximab.38 Normal expression and mutation status of 
PTEN and PI3K, are also needed for normal function of the 
EGFR pathway, as these systems are needed to propagate 
signals further downstream.39,40
Age related changes in the EGF-receptor have been 
examined in cell and animal studies. These studies suggest 
that the EGFR system plays a critical role in age-related 
changed in the colonic mucosa.41 Expression of EGFR as 
well as its activity has been shown to increases with age.42,43 
However the observations in these animal and in vitro studies 
have so far not had any clinical relevance.
Pharmacokinetics
Based on phase I studies, cetuximab was approved with 
a recommended weekly schedule, and an initial dose 
of 400 mg/m2 followed by 250 mg/m2 weekly. Peak 
concentration is reached within approximately 2 hours, 
with a T½ of approximately 90 hours.44–47 The primary 
elimination of cetuximab is through binding and inter-
nalization of the antibody/receptor complex. Secondary 
elimination after saturation of EGFR, is a slower degrada-
tion in the liver and spleen via proteolytic interactions of 
the Fc receptors.48
Tabernero et al were first to suggest an alternative 
schedule of cetuximab as they showed that a biweekly regi-
men (cetuximab 500 mg/m2 every 2 weeks) has a similar 
pharmacokinetic proﬁ  le as the approved weekly schedule.49,50 
A clinical study has demonstrated that the efﬁ  cacy and tox-
icity of biweekly cetuximab/irinotecan is similar to results 
obtained with standard weekly cetuximab/irinotecan.51 
These results have been conﬁ  rmed and prospective trials 
are ongoing.52
Since the pharmacokinetic profile of cetuximab is 
independent of liver metabolism, interactions due to poly-
pharmacy are not to be expected. Reduction of dosage of 
cetuximab in the elderly based on pharmacokinetic data is 
not advised.
Efﬁ  cacy and safety of cetuximab 
in metastatic CRC
Second-line and third-line therapy 
with cetuximab
Efﬁ  cacy of cetuximab was initially proven in patients with 
chemo-resistant mCRC.5,18 The promising activity observed 
in phase I and II studies was ﬁ  rst conﬁ  rmed in the pivotal 
BOND study where 329 patients with irinotecan-resistent 
mCRC were randomized to receive either weekly single 
agent cetuximab (400 mg/m2 loading dose IV in 120 minutes, 
followed by 250 mg/m2 IV in 60 minutes every week) alone 
or cetuximab (as above) in combination with irinotecan 
(administered 60 minutes after cetuximab, resulting in an 
overall treatment time of more than 3 hours).53 The combina-
tion signiﬁ  cantly increased response rate from 11% to 23% 
and prolonged PFS from 1.5 months to 4.1 months. OS was 
not signiﬁ  cantly prolonged, perhaps due to cross-over and 
use of cetuximab/irinotecan as salvage therapy at the time of 
progressive disease (PD) in patients who were randomized 
to cetuximab. The MABEL study conﬁ  rmed the results of 
the BOND study in a large community practice setting in 
which 1147 patients with irinotecan-refractory mCRC were 
treated with cetuximab/irinotecan, response rate was 20% 
and OS was 9.2 months.54
One of the criticisms of the BOND study was the lack of 
a control group and therefore NCIC-CO.17 was planned and 
completed.55 In this important phase III study, 572 patients 
pretreated with irinotecan and oxaliplatin were random-
ized to receive best supportive care (BSC) or cetuximab 
monotherapy (Table 2a). The primary aim was to conﬁ  rm 
an advantage in OS. Compared to BSC, cetuximab was 
associated with a signiﬁ  cant improvement in PFS and OS. 
The median OS was 6.1 months in the cetuximab group and 
4.6 months in the BSC group.
A parallel phase III study (n = 463) using the fully human 
anti-EGFR monoclonal antibody panitumumab (Vectibix®) 
confirmed the value of EGFR inhibition in pre-treated 
patients with mCRC.56 Patients received panitumumab or 
BSC every 2 weeks until PD. Response rate and PFS was 
signiﬁ  cantly improved but OS was not signiﬁ  cantly pro-
longed, perhaps due to cross-over and use of panitumumab 
as salvage therapy in 172 of 232 patients initially treated 
with BSC. Panitumumab was approved for monotherapy of 
refractory mCRC by the US Food and Drug Administration 
in September 2006 and conditionally approved in patients 
with tumors harboring wild-type KRAS by the European 
Medicines Agency (EMEA) in December 2007.6 Presently 
there are no solid data on the combination of panitumumab 
and chemotherapy. In patients with allergic reactions to 
cetuximab, re-treatment with cetuximab is possible if 
patients receive pre-medication, but panitumumab is a good 
alternative in these patients.57,58
The EPIC trial with 1298 mCRC patients resistant to 
oxaliplatin showed that second-line cetuximab/irinotecan OncoTargets and Therapy 2009:2 21
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significantly increased response rate (16% versus 4%) 
and improved PFS (4.0 months versus 2.6 months) over 
just irinotecan alone. EPIC was designed to study OS, 
but there was no difference in OS between the two treat-
ment arms. Nearly half of the irinotecan patients were 
given cetuximab when their cancers progressed and 
this rescue therapy might explain the lack of significant 
difference in OS.59
Indirectly these data suggest that cetuximab/irinotecan 
increase response rate to more than 20%, prolong PFS from 
less than 2 months to more than 4 months and that OS is 
prolonged from around 5 months to 9 months.
As a result of the BOND study the combination of 
cetuximab/irinotecan was approved for patients with 
irinotecan-resistant disease in US and Europe in 2004.5
First-line therapy with cetuximab
Several phase II studies have shown promising activity 
for chemotherapy–cetuximab combinations as first-line 
therapy with response rates as high as 80%, high liver resec-
tion rates and long OS.18,60 Recently the ﬁ  rst phase III data 
(Table 2a) conﬁ  rmed efﬁ  cacy of cetuximab in combination 
with irinotecan or oxaliplatin regimens.61,62
In the CRYSTAL study more than 1200 patients with 
EGFR-expressing mCRC were randomized to FOLFIRI or 
FOLFIRI + cetuximab.61 Response rate (39% versus 47%) 
and resection rate were higher and PFS was signiﬁ  cantly 
prolonged (8.0 months versus 8.9 months). The higher 
response rate and longer PFS were also observed in the OPUS 
study in which 368 patients with mCRC were randomized to 
FOLFOX with or without cetuximab.62
Predicting efﬁ  cacy of cetuximab
High costs of targeted therapies warrant the selection of 
patients that actually beneﬁ  t from the therapy. Until recently, 
the development of skin rash during cetuximab therapy was 
the most promising predictive factor, but focus has changed 
towards assessment of tumor tissue.18,53,63
EGFR expression cannot be used to predict efﬁ  cacy 
because there is no difference in activity in patients with 
EGFR positive and EGFR negative tumors.5,35,64–66
Mutations in KRAS
The extracellular EGFR has an impact on stimulating 
growth in cancer. A number of intracellular downstream 
regulating molecules including KRAS reinforce this signal. 
Mutation in KRAS maintains the growth signal even though 
the extracellular receptor is inhibited. In that way extracel-
lular inhibition is largest in patients with KRAS wild-type 
(non-mutated), which seems to be the case with approxi-
mately 60% of mCRC patients.
In recent years an increasing number of phase II studies 
have demonstrated that KRAS mutant status is a predictive 
marker for lack of efﬁ  cacy of cetuximab (and panitumumab), 
as tumor regression in patients with KRAS mutations is very 
unusual. KRAS mutation status, on the other hand, is not in 
itself a prognostic marker.67,68
In a small study with only 30 mCRC patients, KRAS 
mutations were strongly associated with lack of response to 
cetuximab and with a shorter median OS.69 These prelimi-
nary data were subsequently conﬁ  rmed in a larger series of 
114 patients.38 No patient with KRAS mutations obtained 
response to therapy in contrast to 44% of patients with KRAS 
Table 2a Selected cetuximab studies in patients with metastatic colorectal cancer
Author, year Regimen No of patients RR (%) Median PFS (months) Median OS (months)
Third-line therapy
  Cunningham et al 200453 Cet
Cet + Iri
111
218
11
23*
1.5
4.1*
6.9
8.5
  Jonker et al 200755 BSC
Cet
285
287
0
7*
1.8
1.9*
4.6
6.1*
Second-line therapy
  Sobrero et al 200859 Iri
Cet + Iri
650
648
4
16*
2.6
4.0*
10.0
10.7
First-line therapy
  Van Cutsem 200761 FOLFIRI
FOLFIRI + Cet
598
598
39
47*
8.0
8.9*
–
–
  Bokemeyer et al 200762 FOLFOX
FOLFOX + Cet
169
168
36
46
7.2
7.2
–
–
*Signiﬁ  cant difference.
Abbreviations: Cet, cetuximab; Iri, irinotecan; BSC, best supportive care.OncoTargets and Therapy 2009:2 22
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wild-type. In addition, patients with a KRAS mutation had a 
signiﬁ  cantly shorter PFS (2.1 months versus 7.4 months) and 
shorter OS (10.1 months versus 14.3 months). Several compa-
rable retrospective studies have shown similar data.37,70–73
In these studies, most of patients received cetuximab–
irinotecan in combination but some patients also received 
cetuximab or panitumumab as monotherapy. At the 2008 
ASCO meeting, Di Fiori presented data of 281 patients 
with irinotecan-resistant mCRC who were treated with 
cetuximab–irinotecan in several different studies.74 KRAS 
mutations were detected in 35% of patients. No patient 
with KRAS mutations obtained regression of the tumor – in 
contrast to a response rate of 44% in patients with KRAS 
wild-type. Median PFS (5.0 months versus 3.0 months) 
and OS (13.2 months versus 8.0 months) were signiﬁ  cantly 
prolonged in KRAS wild-type patients.
Recent updates of the two large phase III studies compar-
ing BSC and therapy with cetuximab or panitumumab have 
conﬁ  rmed that KRAS analysis presently is the best way 
to identify patients with the lowest chance to beneﬁ  t from 
EGFR-inhibition, as only 1 patient among a total of more 
than 160 patients with KRAS mutations achieved response 
to EGFR-inhibition.55,56,67,68
At the 2008 ASCO GI Cancer meeting, Tabernero et al 
demonstrated that KRAS status is also associated with 
efﬁ  cacy of cetuximab in patients receiving ﬁ  rst-line therapy 
for mCRC. Patients received initially cetuximab monother-
apy followed 6 weeks later by a combination of FOLFIRI 
and cetuximab.75 KRAS mutations were detected in 41% of 
the tumors. In the ﬁ  rst part of the study, patients with KRAS 
wild-type had a response rate of 27.6% compared with 0% 
for patients with KRAS mutations. In the second part of the 
study response rate was higher (55% versus 32%) and PFS 
was signiﬁ  cantly longer (9.4 months versus 5.6 months) for 
patients with KRAS wild-type.
In the CRYSTAL study more than 1200 patients were 
randomized and the authors succeeded in collecting and 
evaluating KRAS status in tumor tissue from 540 patients 
who were representative of the total population (Table 2b). 
KRAS mutations were detected in 192 patients (35.6%). In 
patients with KRAS wild-type, response rate (43% versus 
59%) and PFS (8.7 months versus 9.9 months) was signiﬁ  -
cantly improved.76 In the OPUS study a similar improvement 
in response rate (37% versus 61%) and PFS (7.2 months ver-
sus 7.7 months) was presented at the ASCO 2008 meeting.77 
Survival data in CRYSTAL were presented at ESMO 2008. 
The improvement in OS (21.0 months versus 24.9 months) 
showed a non-signiﬁ  cant trend in favor of cetuximab, but in 
patients with a KRAS mutations OS did not differ between 
the treatment arms (17.5 versus 17.7 months).78 The authors 
concluded that cetuximab added to chemotherapy in patients 
with KRAS wild-type tumors demonstrated an even more 
pronounced beneﬁ  t than that seen in unselected patients and 
that patients with KRAS mutations seem not to beneﬁ  t from 
cetuximab treatment.
Based on data from the CRYSTAL trial and the OPUS 
trial, the European Commission has extended its cetuximab 
license to ﬁ  rst-line treatment of mCRC patients with KRAS 
wild-type tumors, in combination with chemotherapy.
KRAS mutation status is a predictive marker for all 
relevant clinical endpoints in patients with mCRC receiving 
treatment with cetuximab and chemotherapy. The efﬁ  cacy 
of cetuximab therapy seems conﬁ  ned to patients with KRAS 
wild-type and data suggest that KRAS status should be 
analyzed in all patients with mCRC before therapy with 
cetuximab is commenced.
Ongoing studies will prospectively evaluate efﬁ  cacy of 
cetuximab in combination with chemotherapy in patients 
whose tumors contain KRAS wild-type. In the Nordic 
7.5 phase II trial, patients with KRAS wild-type are treated 
Table 2b Selected randomized cetuximab studies in patients with KRAS wild-type metastatic colorectal cancer
Author, year Regimen No of patients RR (%) Median TTP (months) Median OS (months)
Third-line therapy
  Karapetis et al 200868 BSC
Cet
113
117
0
11*
1.9
3.8*
4.8
9.5*
First-line therapy
  Van Cutsem et al 200878 FOLFIRI
FOLFIRI + Cet
176
172
43
59*
8.7
9.9*
21.0
24.9
  Bokemeyer et al 200877 FOLFOX
FOLFOX + Cet
73
61
37
61*
7.2
7.7*
–
–
*Signiﬁ  cant difference.
Abbreviations: Cet, cetuximab; Iri, irinotecan; BSC, best supportive care.OncoTargets and Therapy 2009:2 23
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with a combination of Nordic FLOX and biweekly cetuximab 
(500 mg/m2 iv in 60 minutes every second week) for a total 
of 8 courses (4 months) followed by biweekly cetuximab 
until progression.79
Cetuximab in elderly patients
Data from prospective clinical trials evaluating cetuximab 
in elderly patients have not been published or presented but 
planned or un-planned subgroup analysis in patients receiving 
cetuximab with or without irinotecan is available.
In the BOND study median age was only 59 years and 
efﬁ  cacy data have not been correlated to age but elderly patients 
more than 80 years were included.53 In the NCIC-CO.17 study 
there was no upper age limit, median age was 63 years and 
patients above 80 years were treated.55 In a planned subgroup 
analysis, no signiﬁ  cant differences in the relative beneﬁ  t (PFS or 
OS) of cetuximab were seen across subgroups as age (separated 
by the age of 65 years). In the “panitumumab-study” median age 
was 62 years and patients above 80 years were also included.56 
In accordance with NCIC-CO.17, an equivalent relative beneﬁ  t 
of cetuximab in terms of PFS was seen in a subgroup deﬁ  ned 
on age (also separated by the age of 65 years). Furthermore, the 
signiﬁ  cant effect of cetuximab therapy seen in all patients with 
KRAS wild-type was also retrieved in elderly patients.67
A single retrospective study has examined efﬁ  cacy and safety 
of cetuximab in elderly patients with mCRC.80 Fifty-six patients 
received cetuximab, most often in combination with irinotecan. 
The median age was as high as 76 years (70 to 84 years) and most 
patients were pretreated with ﬂ  uoropyrimidines, irinotecan and 
oxaliplatin. Response rate was 21%, median PFS was 4.4 months 
and median OS was 16.0 months.
Our own experience is that efﬁ  cacy and toxicity are not 
related to age if therapy is selected according to performance 
status and co-morbidity. In 74 patients who received biweekly 
cetuximab/irinotecan51, we found no correlation between 
age and outcome or toxicity; however only 12 patients and 
5 patients were older than 70 years and 75 years, respectively. 
Efﬁ  cacy data divided according to age (65 years) are shown 
in Table 3.
Lelli et al have recently published an outcome study 
of 144 patients receiving weekly cetuximab (usually in 
combination with irinotecan) for chemo-resistent mCRC. 
Median PFS and OS were 4.0 months and 11.8 months, 
respectively. In univariate analysis performance status, weight 
loss, alkaline phosphatases and skin toxicity were signiﬁ  cantly 
correlated to outcome.81 They also divided patients according 
to age and in accordance with our own outcome study51 Lelli 
et al found similar efﬁ  cacy in elderly patients (65+ years).
Toxicity of cetuximab
Side effects of cetuximab are related to EGFR expression 
in normal tissues. In addition, administration of chimeric 
Table 3 Sub-group analysis according to age for 74 patients receiving biweekly cetuximab and irinotecan51
Characteristic Biweekly cetIri
Age 65 years 65 years
Number 28 46
WHO performance status
 02 0 1 9
 12 1 8
 25 0
 30 1
Duration of CetIri, months (range) 4.7 (0.5–12.2) 4.2 (0.5–12.8)
Response rate
  Complete response (CR) 0 (0%) 1 (3%)
  Partial response (PR) 14 (30%) 5 (18%)
  Stable disease (NC) 21 (46%) 17 (61%)
  Disease control (CR + PR + NC) 35 (76%) 23 (82%)
  Progression (PD) 10 (22%) 4 (14%)
  Not evaluable 1 (2%) 1 (4%)
PFS, months (95% CI), p = 0.2 5.3 (3.5–6.7) 5.8 (4.6–8.6)
OS, months (95% CI), p = 0.6 8.6 (6.3–10.8) 9.1 (6.4–11.8)
Abbreviations: CetIri, cetuximab and irinotecan; PFS, progression-free survival; OS, overall survival.OncoTargets and Therapy 2009:2 24
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antibodies also may give rise to severe allergic reactions in 
1.4%–4.5%.51,53,55,59 If patients develop a severe hypersensitivity 
reaction to cetuximab, panitumumab may be used.58,82,83
The most frequent side effect is an acne-like rash primar-
ily located to seborrheic areas.84 The skin reactions are fully 
reversible within a couple of weeks after cessation of therapy.85 
Several options have been evaluated to ameliorate skin toxicity. 
In a randomized placebo-controlled study, systemic tetracycline 
signiﬁ  cantly decreased the severity of skin reactions but did not 
reduce the incidence of rash.86 Treatment with oral minocycline 
and topical tazarotene has also been tested in a randomized trial. 
Topical tazarotene showed no effect, whereas oral minocycline 
signiﬁ  cantly decreased the number of lesions and itching.87
Cetuximab may cause nausea and diarrhea due to effects 
on the EFGR in the gastro-intestinal tract.53,88 EGFR is strongly 
expressed in the kidneys, particularly in the ascending limb of 
the loop of Henle where the main part of ﬁ  ltered magnesium is 
reabsorbed. Blockade of the EGFR in the kidney may trigger 
hypomagnesemia and in as many as 25% of patients grade 3–4 
hypomagnesemia has been observed.89,90 A recent study has 
shown that the elderly develop hypomagnesemia more rapidly 
than the younger.91 Hypo magnesemia may be corrected by oral 
supplements or IV infusions; however both modalities can be 
cumbersome and ineffective.91,92 Development of hypomag-
nesemia may be a predictive marker of outcome.93
Less frequently reported side effects are paronychia 
seen after 2 to 4 months of cetuximab therapy and extensive 
growth of both eyelashes and eyebrows after long-term treat-
ment with cetuximab.84,85,94
There is no evidence that the side-effects of cetuximab, 
apart from hypomagnesemia, are more severe in elderly 
patients than in younger patients.
Quality of life
In an interview based study setting up hypothetical vignettes 
concerning decisions about treatment, elderly patients did not 
differ from younger in terms of acceptance of chemotherapy. 
However, they differ in terms of willingness to trade survival 
for quality of life.95
Assessment of quality of life has been an important part 
of several cetuximab studies. EPIC and NCIC-CO.17 demon-
strated an improved physical function and global health score 
for patients receiving cetuximab and patients also experienced 
a signiﬁ  cantly longer time before quality of life deteriorated.
Final remarks
Medical treatment of patients with mCRC has changed dra-
matically in the past 5 years, improving survival to 2 years, 
and there is no evidence that this should not be the case in 
ﬁ  t elderly patients.
KRAS status must be analyzed in patients with mCRC 
before therapy with cetuximab is initiated because efﬁ  cacy 
of cetuximab therapy seems conﬁ  ned to patients with KRAS 
wild-type. In these patients there is strong evidence for adding 
cetuximab to first-line chemotherapy and for treatment 
of patients with cetuximab and irinotecan after failure of 
irinotecan- and oxaliplatin-based therapies. Subgroup analyses 
of patients included in trials suggest that elderly patients ben-
eﬁ  ts as much from treatment with cetuximab in combination 
with chemotherapy as younger patients. However in the group 
of frail elderly patients, studies are needed to make any ﬁ  nal 
conclusions.
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